sodium aurothiomalate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4706 12244-57-4

Description:

MoleculeDescription

Synonyms:

  • sodium aurothiomalate
  • aurolate
  • aurothiomalate sodium
  • gold sodium thiomalate
  • sodium aurithiomalate
  • myochrysine
A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis.
  • Molecular weight: 390.07
  • Formula: C4H3AuNa2O4S
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 80.26
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1992 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rheumatoid arthritis 862.56 87.55 689 15474 239526 46430373
Treatment failure 505.79 87.55 344 15819 92743 46577156
Drug ineffective 397.28 87.55 777 15386 677061 45992838
Contraindicated product administered 390.65 87.55 277 15886 79670 46590229
Granuloma skin 330.44 87.55 97 16066 3373 46666526
Sleep disorder 330.04 87.55 204 15959 46591 46623308
Blood parathyroid hormone decreased 320.68 87.55 100 16063 4281 46665618
Joint swelling 317.09 87.55 336 15827 165737 46504162
Drug hypersensitivity 316.15 87.55 404 15759 243421 46426478
Panniculitis 294.75 87.55 100 16063 5604 46664295
Drug intolerance 270.76 87.55 292 15871 146757 46523142
Rheumatoid nodule 260.52 87.55 103 16060 8917 46660982
Red blood cell sedimentation rate increased 259.04 87.55 136 16027 22753 46647146
Soft tissue disorder 250.58 87.55 82 16081 4104 46665795
Skin necrosis 237.17 87.55 95 16068 8509 46661390
Presbyacusis 204.76 87.55 64 16099 2758 46667141
Synovitis 204.09 87.55 169 15994 60906 46608993
Infection 202.60 87.55 240 15923 133352 46536547
Pleural thickening 201.54 87.55 62 16101 2533 46667366
Therapeutic product effect incomplete 196.55 87.55 184 15979 77969 46591930
Therapeutic product effect decreased 195.42 87.55 188 15975 82413 46587486
Pleural fibrosis 193.95 87.55 65 16098 3504 46666395
Blood magnesium increased 192.14 87.55 62 16101 2965 46666934
Drug tolerance decreased 191.50 87.55 62 16101 2997 46666902
C-reactive protein increased 189.27 87.55 159 16004 58431 46611468
Adverse reaction 184.47 87.55 78 16085 8012 46661887
Peripheral swelling 184.17 87.55 249 15914 157822 46512077
Inflammation 184.16 87.55 145 16018 48636 46621263
Deafness neurosensory 179.28 87.55 65 16098 4429 46665470
Ulcer 173.33 87.55 95 16068 17297 46652602
Basal cell carcinoma 171.97 87.55 100 16063 20387 46649512
Hypercalcaemia 169.47 87.55 100 16063 20946 46648953
Drug eruption 165.63 87.55 99 16064 21230 46648669
Pneumonia viral 164.92 87.55 68 16095 6556 46663343
Epigastric discomfort 164.43 87.55 65 16098 5619 46664280
Dyspnoea 156.55 87.55 5 16158 515543 46154356
Loss of personal independence in daily activities 152.14 87.55 139 16024 57044 46612855
Therapeutic response decreased 151.63 87.55 123 16040 43022 46626877
Musculoskeletal disorder 141.48 87.55 80 16083 15465 46654434
Demyelination 136.97 87.55 57 16106 5623 46664276
Skin ulcer 132.27 87.55 101 16062 32357 46637542
Deafness transitory 131.01 87.55 40 16123 1592 46668307
Gastric disorder 124.26 87.55 90 16073 26615 46643284
Arthropathy 118.11 87.55 146 16017 84554 46585345
Impaired gastric emptying 117.76 87.55 57 16106 8015 46661884
Cyst 117.53 87.55 65 16098 12035 46657864
Osteoarthritis 106.53 87.55 119 16044 61906 46607993
Musculoskeletal stiffness 105.82 87.55 149 16014 97844 46572055
Functional gastrointestinal disorder 104.69 87.55 40 16123 3154 46666745
Rash pruritic 103.21 87.55 100 16063 44115 46625784
Osteopenia 99.67 87.55 66 16097 16895 46653004
Fibromyalgia 99.59 87.55 90 16073 36373 46633526
Death 99.09 87.55 4 16159 335544 46334355
Renal impairment 98.55 87.55 125 16038 74247 46595652
C-reactive protein abnormal 97.38 87.55 71 16092 21199 46648700
Blood cholesterol increased 96.23 87.55 92 16071 39921 46629978
Condition aggravated 92.03 87.55 237 15926 244815 46425084
Liver function test abnormal 91.74 87.55 96 16067 46391 46623508
Blood potassium increased 90.08 87.55 62 16101 16905 46652994
Gastrointestinal pain 89.14 87.55 46 16117 7409 46662490
Gastrointestinal disorder 88.36 87.55 106 16057 59470 46610429

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Joint swelling 474.01 160.74 204 4762 46742 29900770
Red blood cell sedimentation rate increased 457.53 160.74 125 4841 7170 29940342
Apparent death 436.05 160.74 104 4862 3438 29944074
Pulmonary thrombosis 366.70 160.74 102 4864 6241 29941271
Rheumatoid arthritis 309.89 160.74 146 4820 41051 29906461
Contraindicated product administered 306.67 160.74 113 4853 17118 29930394
Drug ineffective 288.23 160.74 314 4652 340073 29607439
Diverticulitis 286.98 160.74 108 4858 17337 29930175
Arthropathy 286.36 160.74 113 4853 20614 29926898
C-reactive protein increased 257.67 160.74 131 4835 43342 29904170
C-reactive protein abnormal 251.55 160.74 74 4892 5519 29941993
Terminal state 250.26 160.74 67 4899 3537 29943975
Drug intolerance 207.50 160.74 115 4851 45176 29902336
Thrombosis 190.03 160.74 106 4860 42125 29905387
Photosensitivity reaction 166.44 160.74 62 4904 9632 29937880

Pharmacologic Action:

SourceCodeDescription
ATC M01CB01 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
SPECIFIC ANTIRHEUMATIC AGENTS
Gold preparations
CHEBI has role CHEBI:35842 antirheumatic agent
CHEBI has role CHEBI:37670 protease inhibitors
CHEBI has role CHEBI:50904 allergene
CHEBI has role CHEBI:67079 antiinflammatory agents
CHEBI has role CHEBI:131699 deoxyribonucleic polymerase inhibitor
MeSH PA D018501 Antirheumatic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Juvenile rheumatoid arthritis indication 410795001
Psoriasis with arthropathy off-label use 33339001
Felty's syndrome off-label use 57160007 DOID:11042

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Adenosine receptor A3 GPCR Ki 6.07 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.62 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 6.09 DRUG MATRIX
Thioredoxin reductase 1, cytoplasmic Enzyme WOMBAT-PK
Cathepsin L1 Enzyme IC50 4.05 CHEMBL

External reference:

IDSource
D00992 KEGG_DRUG
4017995 VUID
N0000146340 NUI
4017995 VANDF
C0718739 UMLSCUI
CHEBI:35864 CHEBI
CHEMBL306043 ChEMBL_ID
DB09276 DRUGBANK_ID
D006052 MESH_DESCRIPTOR_UI
22318 PUBCHEM_CID
4154 INN_ID
E4768ZY6GM UNII
203004 RXNORM
2006 MMSL
4795 MMSL
615 MMSL
620 MMSL
d00250 MMSL
002396 NDDF
387380005 SNOMEDCT_US
68702006 SNOMEDCT_US

Pharmaceutical products:

None